Tumor Biology

, Volume 37, Issue 7, pp 9311–9322 | Cite as

SET7/9 inhibits oncogenic activities through regulation of Gli-1 expression in breast cancer

  • Yongchun Song
  • Jianli Zhang
  • Tao Tian
  • Xiao Fu
  • Wenjuan Wang
  • Suoni Li
  • Tingting Shi
  • Aili Suo
  • Zhiping Ruan
  • Hui Guo
  • Yu Yao
Original Article


SET7/9 is a protein lysine methyltransferase that had been initially identified as a histone lysine methyltransferase which generates monomethylation at histone 3 lysine 4. Different functions were attributed to the protein methylation mediated by SET7/9. In this study, we found that the expression of SET7/9 declined in a majority of the human breast cancer tissues examined compared with normal tissues. Knockdown of SET7/9 promoted the proliferation, migration, and invasion of breast cancer cells. Knockdown of SET7/9 also increased the tumorigenicity of breast cancer cells in vivo. On the contrary, overexpression of SET7/9 in breast cancer cells inhibited these processes. Microarray analysis indicated that Gli-1 may play function as a downstream factor of SET7/9. Overexpression of SET7/9SET7/9 inhibits Gli-1 expression. While knockdown of SET7/9 promotes the expression of Gli-1. Gli-1 inhibited by cyclopamine blocked knockdown SET7/9-driven proliferation, migration, and invasion in breast cancer cell. Furthermore, Gli-1 expression in human breast cancer tissues is negatively correlated with SET7/9 expression. Together, these results helped to realize the antioncogene functions of SET7/9 in breast cancer cells and provided a novel direction to treat breast cancer.


SET7/9 Breast cancer Gli-1 Proliferation 



The present study was supported by the Scientific and technological research projects of Shaanxi (Grant no. 2013 K12-12-03)

Compliance with ethical standards

This study was approved by the ethics committee of First Affiliated Hospital of Xi’an Jiaotong University.

Conflicts of interest


Supplementary material

13277_2016_4822_Fig10_ESM.jpg (454 kb)
Supplemental Figure 1

Expression of SET7/9 mRNA was down-regulated in breast cancer tissues. SET7/9 mRNA expreession was analyze by qRT-PCR on breast cancer tissue samples from 79 patients. (JPG 453 kb)


  1. 1.
    DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.CrossRefPubMedGoogle Scholar
  2. 2.
    Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, et al. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014;74(2):520–31.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang Y, Ma G, Wang Q, Wen M, Xu Y, He X, et al. Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells. Molecules. 2013;19(1):159–76.CrossRefPubMedGoogle Scholar
  4. 4.
    Zhang X, Bruice TC. Enzymatic mechanism and product specificity of SET-domain protein lysine methyltransferases. Proc Natl Acad Sci U S A. 2008;105(15):5728–32.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hu P, Wang S, Zhang Y. How do SET-domain protein lysine methyltransferases achieve the methylation state specificity? Revisited by Ab initio QM/MM molecular dynamics simulations. J Am Chem Soc. 2008;130(12):3806–13.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Wilson JR, Jing C, Walker PA, Martin SR, Howell SA, Blackburn GM, et al. Crystal structure and functional analysis of the histone methyltransferase SET7/9. Cell. 2002;111(1):105–15.CrossRefPubMedGoogle Scholar
  7. 7.
    Couture JF, Collazo E, Hauk G, Trievel RC. Structural basis for the methylation site specificity of SET7/9. Nat Struct Mol Biol. 2006;13(2):140–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Kwon T, Chang JH, Kwak E, Lee CW, Joachimiak A, Kim YC, et al. Mechanism of histone lysine methyl transfer revealed by the structure of SET7/9-AdoMet. EMBO J. 2003;22(2):292–303.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Xiao B, Jing C, Wilson JR, Walker PA, Vasisht N, Kelly G, et al. Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature. 2003;421(6923):652–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Liu M, Zhang W, Tang W, Wang Y, Zhao X, Wang X et al. Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells. Tumour Biol. 2015. Epub.Google Scholar
  11. 11.
    Fujimaki K, Ogihara T, Morris DL, Oda H, Iida H, Fujitani Y, et al. SET7/9 enzyme regulates cytokine-induced expression of inducible nitric-oxide synthase through methylation of lysine 4 at histone 3 in the islet beta cell. J Biol Chem. 2015;290(27):16607–18.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lezina L, Aksenova V, Fedorova O, Malikova D, Shuvalov O, Antonov AV, et al. KMT Set7/9 affects genotoxic stress response via the Mdm2 axis. Oncotarget. 2015;6(28):25843–55.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    He S, Owen DR, Jelinsky SA, Lin LL. Lysine methyltransferase SETD7 (SET7/9) regulates ROS signaling through mitochondria and NFE2L2/ARE pathway. Sci Rep. 2015;5:14368.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Munro S, Khaire N, Inche A, Carr S, La Thangue NB. Lysine methylation regulates the pRb tumour suppressor protein. Oncogene. 2010;29(16):2357–67.CrossRefPubMedGoogle Scholar
  15. 15.
    Campaner S, Spreafico F, Burgold T, Doni M, Rosato U, Amati B, et al. The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo. Mol Cell. 2011;43(4):681–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Kurash JK, Lei H, Shen Q, Marston WL, Granda BW, Fan H, et al. Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol Cell. 2008;29(3):392–400.CrossRefPubMedGoogle Scholar
  17. 17.
    Macaron NC, Cohen C, Chen SC, Arbiser JL. gli-1 Oncogene is highly expressed in granulomatous skin disorders, including sarcoidosis, granuloma annulare, and necrobiosis lipoidica diabeticorum. Arch Dermatol. 2005;141(2):259–62.CrossRefPubMedGoogle Scholar
  18. 18.
    Sananto D, Noer S, Alsagaff JH. Gli-1 oncogene: the key to keloidogenesis? Plast Reconstr Surg. 2007;119(3):1146–7.CrossRefPubMedGoogle Scholar
  19. 19.
    ten Haaf A, Bektas N, von Serenyi S, Losen I, Arweiler EC, Hartmann A, et al. Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. BMC Cancer. 2009;9:298.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lei J, Fan L, Wei G, Chen X, Duan W, Xu Q, et al. Gli-1 is crucial for hypoxia-induced epithelial-mesenchymal transition and invasion of breast cancer. Tumour Biol. 2015;36(4):3119–26.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang ZS, Shen Y, Li X, Zhou CZ, Wen YG, Jin YB, et al. Significance and prognostic value of Gli-1 and Snail/E-cadherin expression in progressive gastric cancer. Tumour Biol. 2014;35(2):1357–63.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Yongchun Song
    • 1
  • Jianli Zhang
    • 2
  • Tao Tian
    • 3
  • Xiao Fu
    • 3
  • Wenjuan Wang
    • 3
  • Suoni Li
    • 4
  • Tingting Shi
    • 3
  • Aili Suo
    • 3
  • Zhiping Ruan
    • 3
  • Hui Guo
    • 3
  • Yu Yao
    • 3
  1. 1.Department of Oncological SurgeryFirst Affiliated Hospital of Xi’an Jiaotong UniversityXi’anChina
  2. 2.Department of General SurgeryThe Center Hospital of Xi’anXi’anChina
  3. 3.Department of OncologyFirst Affiliated Hospital of Xi’an Jiaotong UniversityXi’anChina
  4. 4.Department of OncologyShaanxi Province Tumor HospitalXi’anChina

Personalised recommendations